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1139-52 Biolimus A9: A New Generation Rapamycin Analogue 
Inhibits Intimal Hyperplasia in a Porcine Model
Saibal Kar, Joseph Aragon, Alexander Paresky, Fermin Tio, John Shulze, Ronald Betts, 
Neal Eigler, Frank Litvack, Cedars Sinai Medical Center, Los Angeles, CA
Background: Biolimus A9 is a novel, rapamycin analogue especially designed for drug
eluting stent application . Biolimus A9 is developed with the intent of optimizing release
kinetics and tissue partitioning while maintaining the inhibitory properties of Sirolimus on
smooth muscle cells.
Methods: Nine Bare metal(B) and 9 BiolimusA9(B9) coated stents were evaluated in 28
day ovestretch porcine model. The drug delivery polymer was thin layer bio-resorbable
Poly-lactic-acid. The average balloon artery ratio was 1.18±0.3. At sacrifice coronary
angiography and histologic analysis was performed for each stented vessel.
Results: The results are tabulated in Table 1. There was no difference of injury in both
groups. There was 50% reduction of area stenosis by the B9 coated stent(p=0.001). His-
tology, showed near complete endotheliazation in both control and A9 groups with a only
a slight increase in fibrin content in the B9 group.Conclusions; BiolimusA9 delivered via
bioresorbable polymer coated stent inhibits intimal hyperplasia in a porcine model. There
is normal healing of treated arteries at 28days and no inflammation as compared to con-
trols.A first-in man clinical trial has been intiated
1139-53 The Long-Term Clinical Results of a Platelet 
Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: 
ReoPro®) Coated Stent in Patients With Coronary Artery 
Disease
Weon Kim, Myung Ho Jeong, Young Keun Ahn, Ju Han Kim, Young Joon Hong, Jeong 
Gwan Cho, Jong Chun Park, Jung Chaee Kang, Chonnam National University Hospital, 
GwangJu, South Korea
Background : Previously we reported the inhibition of coronary restenosis with Abcix-
imab(ReoPro®)-coated stent in a porcine model. ReoPro® inhibits platelet aggregation,
the proliferation of vascular smooth muscle cells and inflammatory reaction.
Methods : We performed a prospective randomized trial to compare two types of stents
for the revascularization in native coronary artery. The primary effective end points were
major adverse coronary events (MACE): cardiac death, acute myocardial infarction, tar-
get vessel revascularization (TVR), restenosis at 6-month clinical and angiographic fol-
low-up.
Results : One hundred fifty-five patients were enrolled between Aug, 2001 and Jun,
2003. Mean ages (56.0±10.0 vs. 56.9±10.8 years), baseline diameter stenosis and mini-
mal luminal diameter were not different between the two groups. There was one myocar-
dial infarction and revascularization during hospital stay in control stent group. During
clinical follow-up, there were two myocardial infarctions in control group. Follow-up coro-
nary angiogram was done 62.3% (48/77) in coated and 65.4% (51/78) in control groups.
Diameter stenosis and late loss were significantly less in the ReoPro®-coated stent group
compared with controls (16.4±5.8% vs. 34.3±6.1%, p=0.009; and 0.33±0.28 mm vs.
0.88±0.41 mm; p=0.002). The restenosis and TVR rates of ReoPro®-coated stent were
relatively lower compared with control stent [14.6%(7/48) vs. 29.4%(15/51), p=0.062; and
9.2%(7/76) vs. 14.7%(11/75); p=0.327].
Conclusion : A ReoPro®-coated stent is safe and may be effective in the prevention of
coronary restenosis.
1139-54 Nitric Oxide Through Biodegradable Layer Elective 
Study for Safety and Efficacy (NOBLESSE): Final 
Results From the South American Study Arm
Xiaoshun Liu, Costantino Costantini, Hugo Londero, Hans Bonnier, Ivan De Scheerder, 
The NOBLESSE Investigators, University Hospitals Leuven, Leuven, Belgium
Background: Oxygen free radical scavengers may play a significant role in preventing
neointimal hyperplasia after stent implantation. The Blue Medical TEMPO coronary stent
is characterized by its particular biodegradable PEA coating conjugated with tempamine,
a potent antioxidant substance. Pre-clinical work showed a similar tissue response and
reduced intimal hyperplasia in a porcine coronary stent model using this stent. The aim of
this study was to evaluate the acute safety and efficacy of the TEMPO loaded Blue Med-
ical stent implanted in patients with de-novo single vessel disease.
Methods: This is a multinational, multicenter, 2 armed phase III trial. 45 patients treated
with an intermediate dose (50%) of tempamine loaded on the Blue Medical stent from 2
South American study sites are presented: 64% were male, average age 61 (range 37 -
86) 38% had lesion type B2 or C. One 14 mm or 18mm long stent was used. Minimal
lumen diameter (MLD) and % diameter stenosis (DS) were measured. The primary end-
points are 4m in-stent %DS and late loss determined by QCA. The secondary endpoints
are binary restenosis rate at 4m follow-up and 30 days, 60 days and one year major
adverse cardiac events (MACE) defined as death, MI, CABG & target vessel revascular-
ization.
Results: All the stent implantations were successful except one that resulted in a distal
dissection, treated by an additional coated stent implantation. Two patients were
excluded because of violation of the inclusion and/or exclusion criteria. There was no
MACE at 30 days and 60 days f-up. TLR occurred in 2 patients during the 4m f-up. 4m
angiographic f-up rate was obtained in 98%. QCA: mean reference diameter: 3.01±0.29
mm, % Ds was 64.01±12.20% before, 8.40±4.01% after stent implantation and
30.37±17.03 % at 4m f-up. Late loss was 0.69±0.52. Four patients developed an in-stent
restenosis at 4m resulted in a binary restenosis rate of 9.52%. Final 12m clinical f-up will
be presented
Conclusion: This short term and 4 month results show that implantation of a tempamine
loaded Blue Medical stent is feasible and safe. QCA data showed a low late loss and
binary restenosis rate, therefore suggesting a beneficial effect on neointimal hyperplasia
and in-stent restenosis.
1139-55 Optimal Geometry Is Still Important With Sirolimus-
Eluting Stents: Incomplete Stent Expansion as a Risk 
for Target Lesion Revascularization
Junya Ako, Yoshihiro Morino, Mitsuyasu Terashima, Yasuhiro Honda, Shinjo Sonoda, 
Martin B. Leon, Jeffrey W. Moses, Paul G. Yock, Peter J. Fitzgerald, The SIRIUS 
Investigators, Stanford University, Stanford, CA, Lenox Hill Hospital, New York, NY
Background: Despite the striking reduction in neointimal hyperplasia seen with sirolimus
eluting stents (SES), target lesion revascularization (TLR) has not been completely elimi-
nated. The aim of this IVUS substudy was to clarify procedure-related risk factors for TLR
in sirolimus-eluting stents.
Methods and Results: Angiographic and IVUS data were obtained from SIRIUS, a pro-
spective, randomized, multicenter clinical trial comparing SES (sirolimus-eluting Bx
VELOCITY, Cordis) and bare metal stent (BMS). Post-procedure IVUS measurements in
SES were available in 108 cases. Stent expansion was defined as minimum stent area
(MSA) divided by reference LA. There were 6 TLR cases in SES in this patient cohort.
Table summarizes comparisons between TLR and non-TLR cases. Angiographic lesion
length was longer in TLR cases. With respect to procedure-related factors, TLR cases
had lower maximal pressure, smaller % expansion, and a trend toward smaller MSA.
Conclusions: Incomplete stent expansion may be a risk factor for TLR in sirolimus-elut-
ing stents. Proper mechanical stent deployment to achieve adequate lumen geometry
may further improve the clinical success of this technology. 
1139-56 Impact of Stent Implantation Techniques on Stent Edge 
Neointimal Hyperplasia Following Sirolimus-Eluting 
Stenting
Mieke van den Heuvel, Mamoo Nakamura, Junya Ako, Yoshihiro Morino, Yasuhiro 
Honda, Martin B. Leon, Jeffrey W. Moses, Paul G. Yock, Peter J. Fitzgerald, Alan C. 
Yeung, Stanford University, Palo Alto, CA
Background: IVUS substudy of the SIRIUS trial showed a tendency for neointimal hyper-
plasia (NI) to develop at stent edges after sirolimus-eluting Bx VELOCITY stent (SES)
implantation. However, predictors for this phenomenon have not been clarified. In this
study, we examined the potential risk factors including procedural demographics for stent
Histomorphometric Analysis of the Bare and Biolimus A9 stents
Bare Stent(9) Biolimus A9(9) p value
Injury Score 0.30+ 0.10 0.30+ 0.12 NS
Intimal Hyperplasia(Um) 238 + 24 152 + 14 0.004
Area Stenosis(%) 38 20 0.001
No-TLR TLR P
B/A ratio 1.0±0.1 0.9±0.2 NS
Nominal balloon diameter, mm 3.1±0.5 2.8±0.3 NS
Maximum Pressure, atm 17.0±2.7 14.7±1.0 0.03
Lesion Length, mm 14.2±5.2 18.8±5.0 0.04
MLD, mm 2.7±0.4 2.6±0.2 NS
% diameter stenosis 3.5±8.0 6.4±7.5 NS
Reference lumen area, mm2 6.6±2.3 6.5±0.8 NS
MSA, mm2 6.0±1.8 4.6±0.6 0.07
% Stent Expansion 94±22 71±15 0.03
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edge NI after SES.
Methods: Eight month follow-up volumetric IVUS analyses were performed in 35 patients
treated with single SES. Patients were categorized in the edge group when average NI
area, located 1mm inside the stent from either edge, was greater than average NI area of
the non-edge segment. The impact of procedural aggressiveness was evaluated by
assessment of procedural demographics including maximum pressure, balloon:artery
ratio and the previously described artery injury index (product of maximum pressure and
balloon:artery ratio).
Results: Average NI areas, within 1mm from both edges, were 0.67 ± 0.53 and 0.04 ±
0.09 mm2 in the edge and the non-edge group, respectively. Clinical demographics
including age and diabetes mellitus were not different in the two groups. IVUS and proce-
dural data are presented in the Table.
Conclusions: These results suggest that aggressive stent deployment strategy and
smaller vessel size are risk factors for stent edge neointimal formation following siroli-
mus-eluting stent implantation. A less aggressive strategy, particularly in small vessels,
may be important to optimize the long-term durability of this procedure.
1139-57 Impact of Coronary Artery Bending at Stent Edges on 
Subsequent Plaque Proliferation: A Serial Volumetric 
Itravascular Ultrasound Analysis
Hiroshi Yamaguchi, Hideaki Kaneda, Fumiaki Ikeno, Brian K. Coutney, Shinjo Sonoda, 
Ryouta Sakurai, Yoshihisa Shimada, Paul G. Yock, Peter J. Fitzgerald, Yasuhiro Honda, 
Stanford University Medical Center, Stanford, CA
Background: The significant anti-proliferative effect of drug-eluting stents will ncourage
the use of longer stents to treat diffuse coronary lesions as well as to ensure the full cov-
erage of diseased segment. This strategy, however, potentially leads to chronic stent
edge injury by straightening effect of rigid metal stents. The aim of this study was to
investigate the possible association between vessel bending at stent edges and peri-
stent plaque proliferation following bare metal stenting.
Methods: Serial (baseline and 6 months) angiographic and 3D IVUS images were
obtained in 24 cases treated with an identical bare metal stent (3.0-3.5 mm, 18 mm
length). By quantitative angiography at baseline, vessel bending at the stent edge
(defined as the angle between the tangents of two adjacent segments 5 mm inside/out-
side the stent edge) was evaluated by two independent observers. Volumetric IVUS anal-
yses were also independently performed to obtain serial changes in plaque volume at the
proximal and distal reference segments within 2 mm outside the stent edges.
Results: Overall, vessel bending was 17±11º and 14±8º at the proximal and distal stent
edges, respectively. At 6 months, plaque volume significantly increased by 0.98±1.4
(proximal) and 1.04±1.08mm3 (distal). Plaque increase at both the proximal and distal
edge significantly correlated with the degree of vessel bending at baseline (r=0.481,
p<0.05 and r=0.482, p<0.05, respectively).
Conclusions: Significant vessel bending due to stent implantation may be associated with
increased plaque proliferation at stent edges. Enhanced stent conformability to minimize
chronic stent edge injury may be important in the era of drug-eluting stents.
1139-58 A Randomized Study Comparing a Titanium-Nitride-
Oxide Coated With an Uncoated Stent for Coronary 
Revascularization
Stephan Windecker, The TINOX Study Investigators, Swiss Cardiovascular Center Bern, 
Bern, Switzerland
Background: Experimental data have shown reduced neointimal hyperplasia following
implantation of a titanium-nitride-oxide (TiNOX) coated stents. The objective of the
present study was to evaluate safety and efficacy of TiNOX coated stents for treatment of
de novo coronary artery lesions compared with an uncoated, bare metal stent in a ran-
domized, single-blind, multi-center trial.
Methods: Ninety-two patients (lesion diameter 2.5-3.5 mm, lesion length <15 mm) were
randomly assigned to a TiNOX coated (n=45) or bare metal stent (n=47) of identical
design (slotted tube stent: Omega, AMG, Germany). TiNOX coating was performed by
physical vapor deposition in the vacuum chamber. All stents were manually crimped on a
standard balloon catheter after predilation of the lesion. Dual antiplatelet therapy consist-
ing of acetylsalicylic acid (100 mg qd) and clopidogrel (300mg loading dose, followed by
75 mg qd) was administered for 3 months. Clinical follow-up was performed at 1and 6
months. Pre-, post and follow-up angiograms were analyzed by quantitative coronary
angiography (QCA).
Results: Baseline characteristics were similar in the 2 groups. Lesion length (TiNOX:
13.3±4.0 mm, Control: 12.4±3.3 mm, p=ns) and reference vessel diameter (TiNOX:
2.91±0.40 mm, Control: 2.82±0.31 mm, p=ns) were not different. Device success was
100% in both groups. No stent thrombosis was observed in either group. MACE at 30
days was 2% (1 non-target lesion revascularization) in the TiNOX group and 0% in the
control group (ns). QCA showed a significant reduction in late loss (TiNOX: 0.59±0.64,
Control: 0.94±0.74, p=0.03). Binary restenosis was 15.8% in the TiNOX and 34.1% in the
control group (p=0.06). Target lesion revascularization (TiNOX: 9.1, Control: 27%;
p=0.03) and MACE (TiNOX: 9.1%, Control: 31.1%; p=0.01) at 6 months were significantly
lower in the TiNOX than control group.
Conclusions: Coronary revascularization with TiNOX coated stents is feasible and safe
in patients with de novo coronary artery lesions. TiNOX coated stents significantly reduce
late loss and thus restenosis. TiNOX coated stents were associated with significantly
fewer MACE mainly driven by a decreased need for target lesion revascularization.
1139-59 Intravascular Ultrasound Analysis of the New ABT-578 
Eluting Phosphorylcholine-Coated Stent Implantation to 
De Novo Human Coronary Lesions: The ENDEAVOR I 
Trial
Yoichiro Hongo, Ryota Sakurai, Ian Meredith, Robert J. Whitbourn, John Ormiston, 
Patrick Key, David Muller, Mark Pitney, Con Aroney, Mark Adams, Ali Hassan, Yasuhiro 
Honda, Paul G. Yock, Peter J. Fitzgerald, The ENDEAVOR I Trial Investigators, Stanford 
University, Stanford, CA, Monash Medical Centre, Clayton, Australia
Background: ABT-578, a sirolimus analogue, is a new anti-proliferative agent with prom-
ising preclinical study results. ENDEAVOR I is a multicenter, single-arm trial of the ABT-
578 eluting phosphorylcholine (PC)-coated cobalt-chromium alloy Driver® (Medtronic
Vascular, Santa Rosa, CA) stent in de novo human coronary lesions. The aim of this sub-
study was to evaluate short-term safety of this new drug-eluting stent and its impact on
neointimal proliferation using IVUS.
Methods: IVUS analysis (baseline and 4-month follow-up) was available in 95 out of 100
patients. Seven patients had two stents placed. All stents were 18 mm long and 3.0 / 3.5
mm in diameter.
Results: At baseline, no major plaque protrusion or thrombus was detected over the
stented segment. At 4 months, no late incomplete stent apposition was observed. No sig-
nificant change in minimum luminal area within stented segments was observed between
baseline and 4-month follow-up (6.23 ± 1.51 vs. 6.02 ± 1.71 mm2, NS). Volumetric IVUS
analysis showed that neointimal volume index (neointimal volume / stent length) was
0.32 ± 0.39 mm3/mm (Figure) and percent neointimal volume (neointimal volume * 100 /
stent volume) was 4.5 ± 5.9 %.
Conclusion: Early results of the initial human experience with the ABT-578 eluting PC-
coated stent showed a minimum amount of neointimal proliferation with no apparent
adverse vessel response in the stented segment. Further studies will be warranted to
confirm these favorable observations. 
1139-60 An Intravascular Ultrasound Analysis From FUTURE I, 
the First Human Experience Using Everolimus-Eluting 
Stents: Six- and 12-Month Results
Shinjo Sonoda, Eberhard Grube, Yoshihisa Shimada, Ali H.M Hassan, Paul G. Yock, 
Charles Chan, Hidehiko Honda, Saibal Kar, Alexandra J. Lansky, Peter J. Fitzgerald, 
Yasuhiro Honda, Stanford University Medical Center, Stanford, CA, Heart Center 
Siegburg, Siegburg, Germany
Background: FUTURE I is a prospective, randomized trial to evaluate safety and effi-
cacy of everolimus-eluting stents (EES), coated with a unique bioabsorbable polymer,
compared to conventional metallic stents (MS) in the treatment of de novo coronary
lesions. The purpose of this IVUS substudy was to investigate the long-term antiprolifera-
tive effectiveness of EES compared to MS.
Methods and Results: A total of 36 patients completed the angiographic follow-up at 6
months. To date, IVUS images are available in 35 patients (EES 24; MS 11) at 6 months
and 6 patients (all EES) at 12 months. At baseline, EES achieved stent expansion similar
to MS. No significant differences were observed between groups for minimum stent area
(EES 7.0 ± 2.2 vs. MS 6.4 ± 1.2 mm2; P=NS). However, at 6 months follow-up, minimum
lumen area was significantly larger in EES than in MS (EES 6.9 ± 2.6 vs. MS 4.6 ± 1.5
mm2; P<0.01). EES showed 87% volume reduction in neointimal formation compared to
MS (See figure). There was no significant difference in vessel volume post procedure, or
at 6 months follow-up between groups. In 6 patients, neointimal hyperplasia was still sig-
nificantly suppressed at 12 months follow-up. Qualitative analysis showed no evidence of
unhealed dissections or late stent malapposition in either group.
Conclusion: Everolimus-eluting stents, utilizing a unique bioabsorbable polymer, are
effective in preventing neointimal hyperplasia with no evidence of IVUS-detected adverse
effects. 
Edge NI group (n=15) Non-edge NI group (n=20) P-value
Average lumen area 6.95 ± 1.83 7.51 ± 2.29 0.444
Average vessel area 13.66 ± 3.48 16.36 ± 4.18 0.051
Average stent area 7.22 ± 1.87 7.49 ± 2.27 0.710
Average neointimal area 0.31 ± 0.34 0.04 ± 0.08 0.001
Maximum pressure (atm) 18.13 ± 2.99 15.95 ± 2.91 0.037
Balloon:artery ratio 1.05 ± 0.09 0.99 ± 0.15 0.219
Artery injury index 18.87 ± 2.98 15.95 ± 4.37 0.033
